**Name of Journal:** *World Journal of Hepatology*

**Manuscript NO:** 71625

**Manuscript Type:** LETTER TO THE EDITOR

**COVID-19 and liver disease: Are we missing something?**

Gupta T. COVID-19 and liver disease

Tarana Gupta

**Tarana Gupta,** Department of Medicine, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Rohtak 124001, Haryana, India

**Author contributions:** Gupta T is the guarantor of the study, written, and revised the manuscript critically for important intellectual content.

**Corresponding author: Tarana Gupta, Doctor, MBBS, MD, Professor,** Department of Medicine, Pandit Bhagwat Dayal Sharma Post Graduate Institute of Medical Sciences, Medical Mor, Rohtak 124001, Haryana, India. taranagupta@gmail.com

**Received:** September 15, 2021

**Revised:** October 22, 2021

**Accepted:** February 10, 2022

**Published online:** February 27, 2022

**Abstract**

Since the coronavirus disease 2019 (COVID-19) has hit the world as a pandemic, researchers all over the world have worked on its diagnostics, prognosticating factors, *etc.* The present study showed liver enzymes, especially aspartate aminotransferase (AST) levels, to be high in non-survivors with raised AST/alanine aminotransferase ratio. Considering the non-specific nature of AST with its presence in organs other than liver such as muscle, heart, kidney and brain makes it difficult to interpret. Even pre-existing metabolic syndrome and non-alcoholic fatty liver disease are confounding factors for deranged liver functions detected during COVID-19 disease. Therefore, the results of the study should be taken with caution.

**Key Words:** COVID-19; Liver disease; Transaminases; Non-alcoholic fatty liver disease; Hepatocytes; Cholangiocytes

**©The** **Author(s) 2022.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Citation:** Gupta T. COVID-19 and liver disease: Are we missing something? *World J Hepatol* 2022; 14(2): 479-481

URL: https://www.wjgnet.com/1948-5182/full/v14/i2/479.htm

DOI: https://dx.doi.org/10.4254/wjh.v14.i2.479

**Core Tip:** The presence of angiotensin converting enzyme 2 receptors in liver endothelial cells makes it susceptible to severe acute respiratory syndrome coronavirus 2 injury. The authors have suggested raised aspartate aminotransferase (AST) levels in almost a third of non-survivors along with high AST/alanine aminotransferase ratio. Considering the presence of AST in organs other than liver such as muscle, red blood cells, heart and kidney, makes the interpretation difficult. Additionally, pre-existing non-alcoholic fatty liver disease has also been documented as a risk factor for severe coronavirus disease 2019 (COVID-19) disease. Therefore, more studies are needed for evaluation of AST as a predictive factor for severe COVID-19 disease.

**TO THE EDITOR**

We read with great interest the article by “Madian *et al*[1]”. Limited data is available for hepatic injury in coronavirus disease 2019 (COVID-19) disease. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus causes direct cytopathic effect on hepatocytes. It enters the cell through angiotensin converting enzyme 2 (ACE2) receptors which are ubiquitously present on alveolar epithelium, liver, kidney and blood vessels *etc.* ACE2 receptors are present on endothelium of smaller blood vessels in liver, however, sparse on sinusoidal endothelium. Chai *et al*[2] reported higher ACE2 expression on cholangiocytes (59%) than hepatocytes (2.6%). They also suggested that liver dysfunction in COVID-19 is predominantly due to cholangiocyte dysfunction. The profound cytokine storm generated by lung injury also results in liver dysfunction. The drug-related hepatotoxicity related to the use of acetaminophen, remdesivir, lopinavir/ritonavir, azithromycin *etc.* during treatment of COVID-19 disease plays an additive role in causing deranged liver functions[3]. In addition, use of steroids especially in moderate to severe cases can also cause hepatitis B flare in occult hepatitis B patients.

Only a few studies could highlight liver function tests in patients with COVID-19 in non-cirrhotic patients. Limited studies have shown acute liver injury in 14%-53% of COVID-19 cases. In the present study, aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were elevated in 31% and 3% among non-survivors respectively with 48% having AST/ALT ratio > 1.2. Zhang *et al*[4] showed raised AST levels more frequently in intensive care unit (ICU) patients (62%) than in non-ICU (25%) settings. Interestingly, the present study revealed an increased in-hospital mortality up to 11-and 13-fold with AST levels > 1 ULN and > 2 ULN respectively. Chen *et al*[5] analyzed biochemical profile of 113 deceased and 161 recovered patients in Wuhan, and found abnormal AST levels in 59 (52%) *vs* 25 (16%) and lower serum albumin in 74 (65%) *vs* 22 (14%) patients respectively. In the present study, authors also mentioned the possibility of raised AST levels due to muscle injury resulting from profound cytokine storm in COVID-19 illness, though they have documented normal creatine kinase (CK) values indicating liver involvement. AST is an enzyme which is found in liver, muscle, heart, kidney and brain. Therefore, raised AST levels should be taken with caution. The pattern of liver injury in COVID-19 disease is elevated AST levels more than ALT levels with higher gamma-glutamyl-transferase (transpeptidase) (GGTP) values which is similar to alcoholic hepatitis.

We should not forget that non-alcoholic fatty liver disease (NAFLD) and obesity are associated with symptomatic, severe and complicated COVID-19 disease and is a potential confounder[6]. The studies assessing the role of liver injury on the course of COVID-19 illness have not screened patients for NAFLD, and we are not aware about their basic liver function tests before COVID-19. A pooled analysis of 8 studies in NAFLD and COVID-19 by Sachdeva *et al*[7] revealed NAFLD being a predictor of severe COVID-19 disease after adjustment of presence of obesity (OR: 2.3; 95%CI: 1.9-2.9, *P* < 0.001). Therefore, it may be too early to depend alone on AST levels for the severity and outcome of COVID-19 illness.

**REFERENCES**

1 **Madian A**, Eliwa A, Abdalla H, Aly HAA. Hepatocellular injury and the mortality risk among patients with COVID-19: A retrospective cohort study. *World J Hepatol* 2021; **13**: 939-948 [PMID: 34552700 DOI: 10.4254/wjh.v13.i8.939]

2 **Chai X,** Hu L, Zhang Y, Han W, Lu Z, Ke A. Specific ACE2 expression in cholangiocytes may cause liver damage after 2019-nCoV infection. 2020 Preprint. Available from: Bio-Rxiv2020.02.03.931766 [DOI: 10.1101/2020.02.03.931766]

3 **Grein J**, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, Nicastri E, Oda R, Yo K, Quiros-Roldan E, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D'Arminio Monforte A, Ismail S, Kato H, Lapadula G, L'Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R, Flanigan T. Compassionate Use of Remdesivir for Patients with Severe Covid-19. *N Engl J Med* 2020; **382**: 2327-2336 [PMID: 32275812 DOI: 10.1056/NEJMoa2007016]

4 **Zhang C**, Shi L, Wang FS. Liver injury in COVID-19: management and challenges. *Lancet Gastroenterol Hepatol* 2020; **5**: 428-430 [PMID: 32145190 DOI: 10.1016/S2468-1253(20)30057-1]

5 **Chen T**, Wu D, Chen H, Yan W, Yang D, Chen G, Ma K, Xu D, Yu H, Wang H, Wang T, Guo W, Chen J, Ding C, Zhang X, Huang J, Han M, Li S, Luo X, Zhao J, Ning Q. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. *BMJ* 2020; **368**: m1091 [PMID: 32217556 DOI: 10.1136/bmj.m1091]

6 **Mushtaq K**, Khan MU, Iqbal F, Alsoub DH, Chaudhry HS, Ata F, Iqbal P, Elfert K, Balaraju G, Almaslamani M, Al-Ejji K, AlKaabi S, Kamel YM. NAFLD is a predictor of liver injury in COVID-19 hospitalized patients but not of mortality, disease severity on the presentation or progression - The debate continues. *J Hepatol* 2021; **74**: 482-484 [PMID: 33223215 DOI: 10.1016/j.jhep.2020.09.006]

7 **Sachdeva S**, Khandait H, Kopel J, Aloysius MM, Desai R, Goyal H. NAFLD and COVID-19: a Pooled Analysis. *SN Compr Clin Med* 2020: 1-4 [PMID: 33173850 DOI: 10.1007/s42399-020-00631-3]

**Footnotes**

**Conflict-of-interest statement:** I have no conflict of interest.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

**Provenance and peer review:** Invited article; Externally peer reviewed.

**Peer-review model:** Single blind

**Corresponding Author's Membership in Professional Societies:** American Association for the Study of Liver Diseases, No. 226223; Indian National Association for the Study of Liver Diseases, No. 1319.

**Peer-review started:** September 15, 2021

**First decision:** October 18, 2021

**Article in press:** February 10, 2022

**Specialty type:** Gastroenterology and hepatology

**Country/Territory of origin:** India

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**P-Reviewer:** Du Y, Marchesini G **S-Editor:** Fan JR **L-Editor:** Filipodia **P-Editor:** Fan JR



Published by **Baishideng Publishing Group Inc**

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

**Telephone:** +1-925-3991568

**E-mail:** bpgoffice@wjgnet.com

**Help Desk:** https://www.f6publishing.com/helpdesk

https://www.wjgnet.com



**© 2022 Baishideng Publishing Group Inc. All rights reserved.**